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Background: The treatment of oral squamous cell carcinoma (OSCC) following early detection is associated with
good outcomes. Therefore, the survival and prognosis of OSCC patients could be hugely improved by identifying
reliable biomarkers for the early diagnosis of the disease. Our previous methylation microarray analysis results have
suggested that the gene encoding tissue factor pathway inhibitor-2 (TFPI-2) is a potential clinical predictor as well
as a key regulator involved in OSCC malignancy.
Methods: Methylation of the TFPI-2 promoter in oral tissue specimens was evaluated by bisulfite sequencing assay,
quantitative methylation-specific PCR, and pyrosequencing assay. The differences in methylation levels among the
groups were compared using the Mann–Whitney U test. The area under the receiver operating characteristic curve
(AUROC) was used to evaluate the discrimination ability for detecting OSCC. Cellular TFPI-2 expression was analyzed
by quantitative reverse-transcription PCR before and after treatment with 5′-aza-2′-deoxycytidine and trichostatin A,
to confirm whether TFPI-2 was epigenetically silenced in OSCC cells. We investigated whether TFPI-2 plays a role
as a tumor suppressor by establishing TFPI-2-overexpressing OSCC cells and subjecting them to in vitro cellular
proliferation, migration, and invasion assays, as well as an in vivo metastasis assay.
Results: TFPI-2 was hypermethylated in OSCC tissues versus normal oral tissues (P < 0.0001), with AUROC = 0.91,
when using a pyrosequencing assay to quantify the methylation level. TFPI-2 silencing in OSCC was regulated by
both DNA methylation and chromatin histone modification. Restoration of TFPI-2 counteracted the invasiveness of
OSCC by inhibiting the enzymatic activity of matrix metalloproteinase-2, and consequently interfered with OSCC
metastasis in vivo.
Conclusions: Our data suggest strongly that TFPI-2 is a down-regulated tumor suppressor gene in OSCC, probably
involving epigenetic silencing mechanisms. The loss of TFPI-2 expression is a key event for oral tumorigenesis,
especially in the process of tumor metastasis.
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Oral squamous cell carcinoma (OSCC), which consti-
tutes more than 90% of oral cancers arising from the
oral cavity [1], is not only one of the most frequently oc-
curring cancers worldwide, but is also particularly preva-
lent in Taiwan. Oral cancer has been the fourth leading
cause of death from cancer among males in Taiwan since
2003 [2]. As a molecularly heterogeneous disease, OSCC
is strongly associated with risk factors including alcohol,
tobacco, and betel nut consumption [3-6]. OSCC is a
particularly troublesome cancer due to its rapid progres-
sion and frequent metastasis [7], causing deaths at an in-
creasing rate in Taiwan [2]. The treatment of oral cancer
following early detection is associated with good out-
comes, but the 5-year survival rate is <30% among pa-
tients with stage IV disease [8]. Therefore, identifying
reliable biomarkers for the early diagnosis of OSCC may
help to improve the patients’ survival and prognosis.
In addition to genetic alterations such as gene muta-
tion [9], loss of heterozygosity [10], and microsatellite
instability [11], epigenetic alterations (particularly hyper-
methylation in the promoter region of regulatory genes)
have been increasingly recognized as key events in oral
tumorigenesis [12]. By taking advantage of the genome-
wide screening approach, we have recently employed the
Illumina GoldenGate Methylation Array to identify
methylated genes in OSCC tissues (unpublished data).
One of the genes identified with this approach was that
encoding tissue factor pathway inhibitor-2 (TFPI-2).
With a molecular weight of 27, 31, or 33 kDa, depending
upon the level of glycosylation [13], TFPI-2 is synthe-
sized and secreted extracellularly mainly by keratino-
cytes, fibroblasts, smooth-muscle cells, synoviocytes, and
endothelial cells [14-17]. As a known Kunitz-type serine
protease inhibitor and placental protein 5 [13,18,19],
TFPI-2 counteracts the activity of several extracellular
matrix (ECM)-associated serine proteases, including
trypsin, plasmin, chymotrypsin, cathepsin G, plasma kal-
likrein, and the factor VIIa-tissue factor complex [20,21].
Previous studies have demonstrated that TFPI-2 sup-
presses tumor invasion and metastasis via its inhibitory
activity on ECM degradation and remodeling [22,23].
Roles of TFPI-2 in induction of the apoptosis pathway
and in angiogenesis have also been demonstrated
[24-27]. It has been shown that TFPI-2 is down-
regulated via epigenetic silencing mechanisms including
promoter hypermethylation and histone deacetylation
in several types of tumor, such as pancreatic ductal
adenocarcinoma [28], melanoma [29], hepatocellular
carcinoma [30], gastric carcinoma [31], and glioma [32].
The level of TFPI-2 methylation was also found to differ
between preoperative and postoperative saliva DNA in
oral cancer patients, highlighting its potential diagnostic
value as a biomarker for oral cancer [33].In the present study we first examined the methylation
level of TFPI-2 in clinical OSCC specimens. Current
techniques used to measure DNA methylation, including
bisulfite sequencing assay, quantitative methylation-
specific PCR (qMSP), and pyrosequencing assay, were
applied to uncover the DNA methylation status of the
TFPI-2 promoter region. The methylation level of TFPI-
2 was further statistically analyzed to determine whether
there was any correlation with the pathological stages of
OSCC patients. We then restored the gene expression of
TFPI-2 in OSCC cell lines by using epigenetic drugs and
employing lentivirus vector-mediated gene transfer of
TFPI-2. Restoration of TFPI-2 significantly suppressed
the invasion and metastasis of OSCC cells. Our data
strongly suggest that epigenetic silencing of TFPI-2 plays
an important role in oral tumorigenesis.
Methods
Collection of oral tissue specimens and bisulfite
conversion of genomic DNA
Normal oral tissues, OSCC tissues and their correspond-
ing non-tumor tissues were obtained from the tissue
banks of China Medical University Hospital and Bud-
dhist Tzu Chi General Hospital in Taiwan. Genomic
DNA of the tissues was isolated using Gentra Puregene
Tissue Kit (Qiagen, Valencia, CA) and 500 ng of gen-
omic DNA was subjected to bisulfite conversion using
EZ DNA methylation kit (Zymo Research, Orange, CA).
Bisulfite conversed Universal Methylated Genomic DNA
(Millipore, Billerica, MA,) was used as in-vitro methyl-
ated DNA (IVD) control for the methylation level deter-
mined by qMSP and pyrosequencing assays.
Bisulfite sequencing assay and real-time quantitative
methylation-specific PCR
For bisulfite sequencing, the primers targeting the pro-
moter region near the TFPI-2 transcription start site were
used for PCR as previously described [30]. The PCR prod-
ucts were separated by gel electrophoresis, purified with a
QIAquick gel extraction kit (Qiagen, Valencia, CA, USA),
cloned into the yT&A cloning vector (Yeastern Biotech,
Taipei, Taiwan), and sequenced. For real-time qMSP,
primers targeting the promoter region of TFPI-2 were as
follows: forward, 5′-ATAAAGCGGGTATTCGGGTC-3′;
reverse, 5′-CTCCGCCGATTAAAAAAA-3′. Real-time
qMSP was performed using ABI StepOne real-time PCR
system according to the manufacturer’s instructions (Ap-
plied Biosystems, Forster City, CA). As an input control
for real-time qMSP, a DNA fragment devoid of any CpG
dinucleotide in ACTB was amplified using the following
primers: forward, 5′-TGGTGATGGAGGTTTAGTAA
GT-3′; reverse, 5′-AACCAATAAAACCTACTCCCT
TAA-3′. The extents of methylated TFPI-2 and ACTB
were determined by the threshold cycle number for each
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lated as the ratio of TFPI-2 to ACTB of a sample divided
by the same ratio of IVD.
Pyrosequencing methylation assay
To further verify the results of bisulfite sequencing and
qMSP, pyrosequencing primers were designed for the
region of interest using Pyromark Assay Design v2.0
(Qiagen): forward, 5′-Bio+GGGTGATAGTTTTAGTG
TATGAATTAGTT-3′; reverse, 5′-CTAAACAACATC
CCCCAATACAACCTC-3′; reverse sequencing primer,
5′-ACTTTCTACTCCAAAC-3′. Pyrosequencing assay
was carried out using the PyroMark Q24 System (Qia-
gen) according to the manufacturer’s instructions.
Epigenetic drug treatment
1 × 106 OSCC cells were seeded onto 10-cm culture
dishes and treated with 0.5 μM or 5 μM 5′-aza-2′-deox-
ycytidine (5-azaDC) (Sigma, St Louis, MO) for 72 h
followed by 0.25 μM trichostatin A (TSA) (Sigma) or
DMSO for 12 h. For TSA treatment alone, cells were in-
cubated with DMSO for 72 h followed by 0.25 μM TSA
for 12 h. Drugs and culture medium were refreshed
every 24 h during the treatments.
Quantitative reverse-transcription PCR
Total RNA was extracted from cell lines using REzol
(Protech, Taipei, Taiwan) according to the manufac-
turer’s protocol. Complementary DNA (cDNA) was syn-
thesized from 1 μg of total RNA using Superscript III
reverse transcriptase (Invitrogen). Quantitative reverse-
transcription PCR (qRT-PCR) was performed using ABI
StepOne real-time PCR system as the following steps:
95°C for 10 min, followed by 50 cycles of successive in-
cubation at 95°C for 15 sec and at 68°C for 45 sec. TFPI-2
and GAPDH cDNA were amplified with the following
primers: TFPI-2 forward, 5′-GCGATGCTGCTCAGGA
G-3′ and reverse, 5′-TCTGCGTGTACCTGTCGTAG
TAG-3′; GAPDH forward, 5′-TTGACGGTGCCATGGA
ATTT-3′ and reverse, 5′-GCCATCAATGACCCCTT
CATT-3′. TFPI-2 expression was normalized against that
of GAPDH.
Quantitative chromatin immunoprecipitation-PCR
Chromatin immunoprecipitation (ChIP)-PCR was per-
formed as previously described [34]. In brief, 2 × 106
OSCC cells were cross-linked with 1% formaldehyde and
washed with PBS in the presence of protease inhibitors.
Cells were homogenized and their chromatin was sub-
jected to ChIP using magnetic Dynal beads (Invitrogen)
and antibody against acetylated or trimethylated lysine 9
of histone H3 (H3K9) (Millipore, Temecula, CA). Fold-
enrichment of amplified DNAs by ChIP was assessed
using protocols as previously described [35]. Specificprimers targeting the promoter region of TFPI-2 were as
follows: R1-forward, 5′-GCAGGTCATTTCCGTCTAGC
TT-3′ and R1-reverse, 5′-ACCTGCCTCCCAAACTTT
CTC-3′; R2-forward, 5′-ACCACTTTCCCTCTCTTT
TGCT-3′ and R2-reverse, 5′-TCGTAGTAGTAACGGA
GAAGTAGGGC-3′.
Cell lines
The OSCC cell lines OC2 and OCSL [36], derived from
Taiwanese male patients who had habits of alcohol
drinking, cigarette smoking, and betel nut chewing, were
maintained in RPMI medium supplemented with 10%
FBS (Invitrogen, Federick, MD). HEK293T cells were
grown in DMEM medium supplemented with 10% FBS.
Plasmid construction and cell infection
The full-length human TFPI-2 cDNA (~0.7 kb) was
cloned from the immortalized ovarian surface epithelia
cell line IOSE [37] by RT-PCR with primers 5′-TTT
CTCGGACGCCTTGCC-3′ and 5′-GAATGTTTAAAA
TTGCTTC-3′. The cDNA was introduced into a lenti-
viral vector plasmid pSin-IRES-GFP (pIG) [38] at the
EcoRI and XbaI sites to generate pSin-TFPI2-IRES-GFP
(pTIG). The plasmids pIG, pTIG and pSin-FLuc-IRES-
GFP (pFIG, a firefly luciferase-expressing lentiviral vector
plasmid) were transiently transfected into HEK293T cells
and at 48 h posttransfection the lentivirus-containing
supernatants were collected for infection. Successful in-
fection was monitored by GFP expression and the in-
fected cells were sorted by FACSAria III Cell Sorter (BD
Bioscience, Franklin Lakes, NJ).
Extracellular matrix protein extraction and immunoblot
assay
Cells were grown to ~90% confluence in culture dishes
and extracellular matrix (ECM) proteins was harvested
from the cells as described by Ehrlich et al. [39]. Briefly,
cells were washed three times with PBS and lysed
through the incubation with PBS containing 0.5% Triton
X-100 for 20 min at room temperature. The cells were
washed three times with PBS and another three times
with 20 nM Tris–HCl [pH 7.4] containing 100 mM
NaCl and 0.1% Tween 20. Finally, 200 μl of 1 × SDS-
PAGE sample buffer was added to the culture dishes and
agitated for 20 min at room temperature. The collected
ECM proteins were boiled and 50 μl of aliquots of the
extracts was assayed using 12% polyacrylamide gels. The
expression of TFPI-2 protein was detected by a poly-
clonal antibody against TFPI-2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA).
Cell proliferation assay
The lentiviral vector-infected cells were seeded onto repli-
cate 96-well plates (500 cells per well). Cell proliferation
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Aqueous One Solution Cell Proliferation Assay kit (Pro-
mega, Madison, WI, USA). Relative cell number was mea-
sured on an ELISA plate reader with an absorbance set at
a wavelength of 490 nm.
Cell cycle analysis
The lentiviral vector-infected cells were seeded onto rep-
licate 6-well plates (1 × 105 cells per well). After 48 h,
the cells were collected, washed, and fixed in 75% etha-
nol at −20°C for 48 h. The cells were then treated with
0.1 mg/ml RNase A (Macherey-Nagel, Düren, Germany),
stained with 10 μg/ml propidium iodide (Sigma), and an-
alyzed by FACSCalibur (BD Biosciences). The percentage
of apoptotic cells in sub-G1 area was quantified using
CellQuest Pro software (BD Biosciences).
Matrigel invasion assay
Invasion assay was done on 6-well Transwells (Milli-














Figure 1 Bisulfite sequencing of TFPI-2 in normal oral and OSCC tissu
comprising 31 CpG sites. The distribution of CpG sites (vertical bar) and the
(BS) and quantitative methylation-specific PCR (qMSP) are shown. Two CpG
the 11 CpG sites analyzed by pyrosequencing assay are boxed. (B) Represe
For each tissue sample, five randomly chosen clones were sequenced and
circles: closed and open circles represent methylated and unmethylated Cppore size). Two × 104 cells were suspended in 200 μl of
RPMI medium supplemented with 0.5% FBS and seeded
on the upper chamber well. The lower chamber well was
filled with RPMI medium containing 10% FBS. After
48 h of incubation at 37°C, nonpenetrating cells were re-
moved from the upper surface of the filter and penetrat-
ing cells on the lower surface of the filter were fixed
with methanol and stained with Giemsa solution
(Sigma). The numbers of penetrating cells were counted
under a light microscope.
Collagen zymography
The inhibitory effect of TFPI-2 on enzymatic activity of
matrix metalloproteinases (MMPs) was assayed by colla-
gen zymography. Two × 105 OC2 cells were suspended
in complete medium and plated onto culture dishes.
After 48 h of incubation, the medium was changed to
serum-free RPMI and the cells were incubated for an-
other 24 h. The conditioned medium was collected and
the protein concentrations were determined by BCA+141+100
es. (A) The region centering on the TFPI-2 transcription start site,
position of the hybridized PCR primer pairs for bisulfite sequencing
sites in the qMSP forward primer are indicated (filled triangles), and
ntative bisulfite sequencing assay for normal oral and OSCC tissues.
the methylation status of each of the 31 CpG sites is indicated by the
G sites, respectively.
Table 1 Selected patients’ characteristics
(a) TFPI-2 methylation level by qMSP
n (%) Mean SD Median IQR
Gender
Male 110 (100) 13.64 13.05 8.94 21.06
Pathological Stage
Normal 24 (21.8) 4.45 7.51 1.79 1.62
I 20 (18.2) 16.23 12.97 13.87 16.71
II 12 (10.9) 12.96 12.46 6.96 23.95
III 25 (22.7) 17.19 13.62 16.86 23.15
IV 29 (26.4) 16.67 13.60 16.64 19.61
Cancer Site
Buccal 36 (41.9) 17.05 12.46 15.95 18.90
Tongue 50 (58.1) 15.59 13.71 11.66 22.63
(b) TFPI-2 methylation level by pyrosequencing
n (%) Mean SD Median IQR
Gender
Male 60 (100) 18.80 14.99 15.58 23.79
Pathological Stage
Normal 11 (18.3) 4.43 1.91 3.82 2.94
I 15 (25.0) 20.35 12.19 18.26 23.14
II 12 (20.0) 16.21 9.48 12.17 12.97
III 14 (23.3) 21.63 16.08 21.03 28.34
IV 8 (13.3) 34.63 18.06 33.10 23.50
Cancer Site
Buccal 19 (38.8) 29.70 14.41 28.12 16.07
Tongue 30 (61.2) 17.18 12.96 13.86 20.82
SD: standard deviation; IQR: interquartile range.
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Figure 2 Methylation status of TFPI-2 determined by qMSP assay. (A)
assay. The amount of methylated TFPI-2 was normalized to the amount of
N, normal oral tissues; P1–P4, OSCC tissues classified according to patholog
percentiles, the lower and upper limits of the box indicate the 25th and 75
using TFPI-2 methylation to detect OSCC. The AUROC was 0.79. (C) ROC cu
(P1 and P2). The AUROC was 0.82.
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proteins was mixed with non-reducing sample buffer
containing 315 mM Tris [pH 6.8], 50% glycerol, 5% SDS
and 0.025% bromophenol for electrophoresis. Without
boiling, the mixed solution was loaded on a 10% poly-
acrylamide gel containing 0.5 mg/ml collagen (Sigma).
After electrophoresis, gel was incubated for 1 h at 25°C
in a 2.5% Triton X-100 solution followed by 20-min
wash with deionized water for 2 times, and then incubated
overnight at 37°C in a 50 mM Tris–HCl [pH 8.0], contain-
ing 5 mM CaCl2. The gel was stained with 0.25% Coomas-
sie blue and destained with 10% methanol and 7% acetic
acid. Enzymatic activity attributed to MMPs can be visual-
ized as clear bands against a blue background. The relative
intensity of the bands was quantified by ImageJ.
In vivo tumor metastasis assay
Athymic BALB/c nude mice were obtained from National
Laboratory Animal Center, Taiwan. Cells at a density of
1 × 106 in 100 μl of PBS were intravenously injected into
the tail veins of athymic BALB/c nude mice. Forty days
after tumor cell inoculation, the mice were sacrificed and
their lungs were excised. The lung tissues were fixed with
10% formaldehyde and the number of pulmonary tumor
nodules on each lung was counted.
Statistical analysis
The Mann–Whitney U test was used to compare the
methylation levels between or among groups of tissue
specimen. Receiver operating characteristic (ROC) curve
and the area under the ROC curve (AUROC) was calcu-
lated to summarize the accuracy of using methylationC
Box plots of the TFPI-2 methylation level as determined by the qMSP
ACTB and is expressed as a percentage of that in IVD (given as 100%).
ical stage. In each box plot, the whiskers represent the 10th and 90th
th percentiles, and the red line is the mean. (B) ROC curve obtained
rve obtained using TFPI-2 methylation to detect early-stage OSCC
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methylation level and OSCC were measured by logistic
regression models. Differences with P < 0.05 were deemed
significant. Analyses were performed in SAS 9.3 (SAS In-
stitute, Cary, NC). Box plots were generated by SigmaPlot
version 10 (Systat Software, San Jose, CA).
Results
TFPI-2 is frequently hypermethylated in OSCC tissues
Based on our recent methylation array analysis involving
specimens of normal oral tissues and OSCC tissues at
different pathological stages, the methylation level of
TFPI-2 was found to differ between normal- and tumor-




















n = 11 15  12 14 8
D
Figure 3 Methylation status of TFPI-2 determined by pyrosequencing
pyrosequencing assay. TFPI-2 methylation level is expressed as a percentag
across all 11 CpG sites was 3.82% in normal oral tissues, and 18.26%, 12.17%
the whiskers represent the 10th and 90th percentiles, the lower and upper
line is the mean. (B) Differential pattern of TFPI-2 methylation at each indiv
tissues. Numbers at the x-axis indicate nucleotide positions of CpG site rela
methylation levels are indicated by asterisks (*). (C) ROC curve obtained us
curve obtained using TFPI-2 methylation to detect early-stage OSCC (P1 ansites (P152, P9, and E141) were all significantly higher in
the tumor tissues than in normal tissues (data not
shown). To validate the methylation array data, we fur-
ther analyzed the methylation status of several oral tis-
sue specimens by bisulfite sequencing assay. As shown
in the target region centering on the TFPI-2 transcrip-
tion start site comprising 31 CpG sites (Figure 1A),
highly dense methylation was observed in the tumor tis-
sues, whereas the normal tissues were essentially free of
methylation (Figure 1B).
To further quantify the methylation level of TFPI-2,
we performed real-time qMSP and pyrosequencing
methylation assays for oral tissue specimens. The se-





















P4 (n = 8)
P1+P2 (n = 27)
assay. (A) Box plots of TFPI-2 methylation level determined by the
e of that in IVD (given as 100%). The median methylation percentage
, 21.03%, and 33.10% in P1–P4 tumors, respectively. In each box plot,
limits of the box indicate the 25th and 75th percentiles, and the red
idual CpG site between early-stage (P1 and P2) and late-stage (P4)
tive to the transcription start site. Statistically significant differences in
ing TFPI-2 methylation to detect OSCC. The AUROC was 0.91. (D) ROC
d P2). The AUROC was 0.94.
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samples were subjected to pyrosequencing methylation
assay. The methylation level is summarized as mean and
standard deviation values or median and interquartile

















































































































Figure 4 Reactivation of TFPI-2 using epigenetic drugs. (A) RT-PCR ana
both. 0.5A, 0.5 μM 5-azaDC; 5A, 5 μM 5-azaDC; TSA, 0.25 μM TSA; 0.5A + T,
TSA. The mRNA level of TFPI-2 in OCSL was compared with that of the con
standard deviations. (B) Methylation levels of OCSL and OC2 cells treated w
converted and the percentage of TFPI-2 methylation was determined using
as a percentage of that in IVD (given as 100%). The DMSO- and drug-treate
considered statistically significant. (C) Histone modifications at the promote
antibodies against H3K9-Ac and H3K9-me3 in OCSL cells. Regions of the TF
R2. The binding of H3K9-Ac and H3K9-me3 antibodies to regions R1 and R
curve generated from input DNA. The binding level of each antibody in OC
that of the cell treated with DMSO, which was assigned a value of 1.qMSP comprised 86 tumor tissues and 24 normal tis-
sues; the TFPI-2 methylation level was significantly
higher in tumors than in normal tissue (P < 0.0001;
Figure 2A). The median methylation percentages in
































lysis of TFPI-2 expression in OCSL cells treated with 5-azaDC, TSA, or
0.5 μM 5-azaDC and 0.25 μM TSA; 5A + T, 5 μM 5-azaDC and 0.25 μM
trol cell line IOSE, which was assigned a value of 1. Error bars indicate
ith 5-azaDC, TSA, or both. The DNA of OCSL and OC2 was bisulfite
the pyrosequencing assay. The TFPI-2 methylation level is expressed
d groups were compared using Student’s t-test; P < 0.05 (*) was
r region of TFPI-2 in OCSL cells. ChIP assays were performed with
PI-2 promoter for quantitative ChIP-PCR assay are indicated as R1 and
2 was measured by the quantification of ChIP DNA against a standard
SL treated with 5 μM 5-azaDC and 0.25 μM TSA was compared with









































Figure 5 Reexpression of TFPI-2 in OSCC cells by gene transfer.
(A) RT-PCR analysis of TFPI-2 expression in OSCC cells. Experiments
were performed in triplicate and the results are shown as the changes
in the expression relative to IOSE. Neg, untransduced cells; IG, cells
transduced with a control lentiviral vector; FIG, cells transduced
with a firefly luciferase-expressing lentiviral vector; TIG, cells
transduced with a TFPI-2-expressing lentiviral vector. Error bars
indicate standard deviations. (B) Western blot analysis of ectopic
TFPI-2 overexpression in OSCC cells. ECM proteins were extracted
from the cells for Western blot analysis and TFPI-2 isoforms with
molecular weights of 27, 31, and 33 kDa due to different extents
of glycosylation are indicated with arrows. Beta-actin was used as a
loading control.
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value in normal tissues was 1.79% (P < 0.05 for any specific
stage vs the normal tissues). A similar pattern of TFPI-2
methylation status was obtained using pyrosequencing
assay with 60 oral tissue specimens comprising 49 tumor
tissues and 11 normal tissues (P < 0.0001; Figure 3A). The
median methylation percentages in P1–P4 tumors were
18.26%, 12.17%, 21.03%, and 33.10%, respectively, while in
normal tissues it was 3.82% (P < 0.05 for any specific stage
vs the normal tissues). The methylation level differed not
only between the normal and tumor tissues, but also be-
tween the early- and late-stage tumor tissues. Figure 3B
shows the differential pattern of TFPI-2 methylation levels
among the 11 CpG sites between the early-stage (P1 and
P2) and late-stage (P4) tumor tissues. The methylation
levels were significantly higher in the P4 tumors compared
to the P1 and P2 tumors at most of the CpG sites.
TFPI-2 methylation is a good biomarker for OSCC
detection
TFPI-2 hypermethylation could be used to discriminate
tumor tissues from the normal ones. The AUROC values
for using methylation level to detect OSCC were 0.79
(95% confidence interval (CI) = 0.69–0.89; Figure 2B)
and 0.91 (95% CI = 0.83–0.98; Figure 3C) for the qMSP
and pyrosequencing assays, respectively. A 1% increase
in methylation level, as quantified by pyrosequencing
assay, was associated with a 1.49-fold higher of risk of
OSCC (95% CI = 1.06–2.10, P = 0.023), while the odds
ratio was 1.13 (95% CI = 1.05–1.22, P = 0.001) per 1% in-
crease of methylation level when quantified by qMSP.
Moreover, TFPI-2 hypermethylation could be used to
discriminate the early-stage tumor tissues from the nor-
mal ones. The AUROC values for using methylation
level to detect early-stage OSCC (P1 and P2) were 0.82
(95% CI = 0.70–0.94; Figure 2C) and 0.94 (95% CI =
0.87–1.00; Figure 3D) for the qMSP and pyrosequencing
assays, respectively.
Promoter hypermethylation and histone modification
contribute to TFPI-2 inactivation in OCSL cells
Aberrant DNA methylation in the promoter region is a
key mechanism for gene silencing, and so we treated the
OSCC cell lines OCSL and OC2 with the demethylating
agent 5-azaDC to determine whether TFPI-2 expression
could be restored. We also investigated whether histone
modification is involved in TFPI-2 silencing using the
histone deacetylase inhibitor TSA. RT-PCR revealed no
detectable TFPI-2 mRNA expression in OC2 cells irre-
spective of the treatment (data not shown). In OCSL
cells, neither 5-azaDC nor TSA treatment alone induced
the expression of TFPI-2; however, a dramatic increase
in TFPI-2 expression was observed after combined treat-
ment with 5-azaDC and TSA (Figure 4A). In agreementwith TFPI-2 reactivation in OCSL cells, TFPI-2 methyla-
tion levels in OCSL were decreased when treated with
the combination of 5-azaDC and TSA (Figure 4B, left);
in contrast, there was no such effect in OC2 cells
(Figure 4B, right). To further confirm the involvement of
histone modification in TFPI-2 regulation in OCSL cells,
we performed ChIP-PCR assay to analyze histone status
in respect to active and repressive chromatin marks at
the promoter region of TFPI-2 by using antibodies
against acetylated H3K9 (H3K9-Ac) and trimethylated
H3K9 (H3K9-me3). After combined treatment with 5-
azaDC and TSA, higher levels of the active histone mark
H3K9-Ac were found at the TFPI-2 promoter regions. In
contrast, lower levels of the repressive histone mark
H3K9-me3 were found at the same regions (Figure 4C).
Together these observations show that the synergistic ef-
fect of 5-azaDC and TSA inducing a substantial TFPI-2
reexpression implies that both DNA methylation and
histone deacetylation play important roles in TFPI-2 si-
lencing in OCSL.
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The observation of TFPI-2 silencing in OSCC tissues
and cells inspired us to examine the tumor-suppressive
role of TFPI-2 in OSCC. We prepared OSCC cells trans-
duced with TFPI-2-expressing lentiviral vector (TIG)
and confirmed the reexpression of TFPI-2 in the cells by
qRT-PCR (Figure 5A). Western blot analysis also revealed
the presence of TFPI-2 triplets in the ECM of TIG-
transduced OSCC cells, while no such protein expression
was observed in IG-transduced or untransduced cells
(Figure 5B). The effect of restoring TFPI-2 expression in
OSCC was examined by performing cell proliferation,
colony formation, and apoptosis assays. Restoration of
TFPI-2 in OSCC cells did not significantly affect the cell
proliferation rate, the number of colonies being formed,
or the percentage of apoptotic cells (Figure 6).
TFPI-2 suppresses OSCC cell invasion and blocks MMP-2
activity to reduce tumor metastasis in vivo
A Matrigel invasion assay was performed to determine
whether TFPI-2 has an inhibitory effect on OSCC cell
invasion. It was found that TFPI-2 significantly abol-












































Figure 6 Effects of TFPI-2 on the growth of OSCC cells. (A) Effect of TF
assay. (B) Quantitative analysis of the number of colonies formed using the
change in the number of colonies formed. (C) Effect of TFPI-2 on apoptosi
standard deviations.Interestingly, the migratory ability did not differ signifi-
cantly between IG- and TIG-transduced OSCC cells (data
not shown), highlighting the ability of TFPI-2 to inhibit
ECM degradation during the process of metastasis. Colla-
gen zymography was performed on conditioned medium
from the transduced OC2 cells in order to examine
whether tumor-secreted proteases were targeted by TFPI-
2 inhibition. A less-dense band was found at the position
corresponding to the protein size of active MMP-2, dem-
onstrating that the enzymatic activity of MMP-2 was re-
duced in TIG-transduced cells (Figure 7B).
It could be reasoned that TFPI-2 restoration counter-
acted tumor invasion by negatively regulating MMP-2
activation. To confirm the role of TFPI-2 in the suppres-
sion of OSCC metastasis, we performed an experimental
metastasis assay by intravenously injecting transduced
OC2 cells into nude mice. The number of lung meta-
static nodules derived from the circulating cells in each
mouse was counted 40 days after tumor-cell inoculation.
As shown in Figure 8, far fewer metastatic nodules de-
veloped in the TIG group compared to the IG group,
demonstrating that TFPI-2 overexpression restrained










































PI-2 on the cell proliferation of OSCC cells was determined by MTS
colony formation assay. OC2 cells transduced with TIG exhibited no
s of OC2 cells was determined by cell cycle analysis. Error bars indicate
Figure 7 Inhibitory effect of TFPI-2 on OSCC invasion and
MMP-2 enzymatic activity. (A) In vitro cell-invasion assay. Cells
that penetrated the Matrigel-coated filter were fixed, stained, and
counted in at least three fields of view under a microscope.
Comparison between IG and TIG groups was evaluated by Student’s
t-test, and P < 0.05 (*) was considered statistically significant. Error
bars indicate standard deviations. (B) The enzymatic activity of
MMP-2 was determined by collagen zymography. Conditioned
medium containing secreted collagenases was collected from the
transduced OC2 cell cultures and subjected to collagen zymography.
The position of MMP-2 (62 kDa) is indicated by an arrow.
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In this study we applied a high-throughput methylation
array to investigate the DNA methylation status in oral
tissue specimens. Comparison of gene methylation pro-
filing between normal oral and OSCC tissues has sug-
gested that TFPI-2 is hypermethylated in OSCC tissues,
an observation that has been confirmed by qMSP and
pyrosequencing assays. In agreement with the concept
that TFPI-2 methylation is an early event in esophageal
carcinogenesis [40], a significant difference in methyla-
tion level of TFPI-2 was found between normal oral tis-
sues and tumor tissues at early stages, further validating
the clinical value of TFPI-2 methylation profiling for theearly detection of OSCC. In addition, the TFPI-2 methy-
lation level in tumor tissues was higher at the P4 stage
than at earlier stages (P1 and P2). Most of the 11 CpG
sites analyzed by pyrosequencing assay displayed signifi-
cant differences in methylation level between early and
late stages, indicating the trend of increased methylation
with progressive oral tumorigenesis.
While it is clear that TFPI-2 methylation profiling al-
lows clinical samples to be discriminated, the difference
in TFPI-2 mRNA expression between tumor and normal
tissues was not as convincing as was expected (data not
shown), mostly due to the heterogeneity of OSCC tissue
specimens, in which both TFPI-2-expressing and nonex-
pressing cells were present [41]. Therefore, we measured
TFPI-2 mRNA expression in OSCC cell lines and deter-
mined whether TFPI-2 down-regulation was caused by
DNA methylation and histone deacetylation. We success-
fully reactivated TFPI-2 expression in OCSL cells but not
in OC2 cells after combined treatment with 5-azaDC and
TSA. In addition, the extent of TFPI-2 restoration in
OCSL was comparable to that in TIG-transduced OCSL
(3.5-fold vs 4.4-fold changes in TFPI-2 expression relative
to IOSE). It is thus possible that for cells that are nonre-
sponsive to 5-azaDC and TSA, such as OC2, the alterna-
tives of viral or non-viral vector-mediated gene transfer
for achieving sufficient TFPI-2 restoration are candidates
for OSCC therapy.
The mechanism underlying the effect of DNA methy-
lation on the repression of TFPI-2 in breast cancer cell
lines has been reported previously [42]. Sequence ana-
lysis of the TFPI-2 promoter region identified a potential
Kruppel-like factor 6 (KLF6) binding site, suggesting that
the aberrant DNA methylation in the KLF6 binding site
diminishes the binding of transcription factor KLF6 to
the TFPI-2 promoter to decrease TFPI-2 expression.
Furthermore, Konduri et al. reported that methyl-CpG-
binding protein 2 (MeCP2) was associated with the
methylated TFPI-2 promoter using a ChIP assay in hu-
man glioma cells [32]. The loss of MeCP2 from the acti-
vated TFPI-2 after combined treatment with 5-azaDC
and TSA delineated the interplay between histone dea-
cetylation and DNA methylation in the gene-silencing
machinery. Together our findings corroborate the earl-
ier conclusion that both promoter methylation and
chromatin histone modification play important roles in
TFPI-2 down-regulation.
Consistent with our in vitro data showing that TFPI-2
restoration neither suppressed cell proliferation nor pro-
moted cell apoptosis, the tumor size did not differ sig-
nificantly between IG- and TIG- transduced OSCC cells
in a subcutaneous OSCC xenograft model in animals
(data not shown). Although TFPI-2 has been found to
reduce the cell proliferation rate in various human tu-





























Figure 8 TFPI-2 reduced OSCC metastasis in vivo. (A) IG- or TIG-transduced OC2 cells were intravenously injected into the tail veins of athymic
BALB/c nude mice (n = 5 in the IG group; n = 7 in the TIG group). Forty days after tumor cell inoculation, the number of pulmonary metastatic
nodules derived from circulating cells in each mouse was counted. The Mann–Whitney U test was used to compare the numbers of tumor
nodules between groups. *, P = 0.023. (B) Representative photograph of lung tissues excised from the mice.
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feration effect [47-49]. Therefore, the effect of TFPI-2
on cell proliferation and apoptosis may be complex and
cell-type specific.
In the present study we demonstrated that TFPI-2
restoration could significantly abolish the invasiveness
of OCSL and OC2 cells, but had no inhibitory effect on
cell migration. Although TFPI-2 was previously shown
to reduce tumor cell invasiveness, the findings regarding
its influences on cell migration have been controversial
[40,43,45,47,48]. As an inhibitor of ECM degradation,
TFPI-2 has been described as an indirect inhibitor of
MMPs via plasmin inhibition [27,45,47]. Our data also
showed that TFPI-2 counteracts tumor invasion by
negatively regulating MMP-2 activation, consistent with
the finding that TFPI-2 is associated mainly with the in-
hibition of ECM degradation [13]. As also reported by
Izumi et al. [27], TFPI-2 suppressed cell invasion via the
down-regulation of the level of active MMP-2 to inter-
fere with the process of tumor metastasis. In addition,
we successfully established a metastatic tumor model in
animals by the intravenous injection of TFPI-2-express-
ing OC2 cells, and observed a marked inhibitory effect
of TFPI-2 in the formation of lung tumor nodules, dem-
onstrating that TFPI-2 is a silenced tumor suppressor
gene in OSCC.
Conclusions
The significance of the reported differential pattern of
TFPI-2 hypermethylation between normal oral and OSCC
tissues makes it a promising biomarker for the early detec-
tion of OSCC. TFPI-2 expression in OSCC can be reacti-
vated after combined treatment with 5-azaDC and TSA,
revealing a synergistic regulation of DNA methylation and
histone deacetylation in TFPI-2 silencing. Our data sug-
gest that TFPI-2 is a down-regulated tumor suppressorgene in OSCC, and that loss of TFPI-2 expression is a key
event in oral tumorigenesis.
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